|
Study
|
Mulligan et al. [10]
|
Terragna et al. [2]
|
|---|
|
Treatment
|
Bortezomib
|
VTD
|
|
Number of Samples
|
169
|
118
|
|
Number of Probes
|
22,283
|
54,677
|
|
Patients Population
|
Relapsed MM
|
New-Diagnosis
|
| |
Progressive Disease (PD)
|
Stable Disease (SD)
|
| |
13 (7.70%)
|
7 (5.93%)
|
| |
No Change (NC)
|
Partial Response (PR)
|
| |
60 (35.50%)
|
42 (35.59%)
|
| |
Minimal Response (MR)
|
Very good partial response (VGPR)
|
| |
12 (7.10%)
|
40 (33.90%)
|
| |
Partial Response (PR)
|
near Complete Response (nCR)
|
| |
43 (25.44%)
|
14 (11.87%)
|
| |
Complete Response (CR)
|
Complete Response (CR)
|
| |
41 (24.26%)
|
15 (12.71%)
|
